NCT04677049View on ClinicalTrials.gov

Study of Niacin in Glioblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
DRUG

Niacin CRT

A controlled release technology (CRT) tablet of Niacin

Trial Locations (1)

T2N 4N2

RECRUITING

Tom Baker Cancer Centre, Calgary

All Listed Sponsors
collaborator

Tom Baker Cancer Centre

OTHER

lead

AHS Cancer Control Alberta

OTHER